Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

8.65
-0.5200-5.67%
Volume:492.87K
Turnover:4.30M
Market Cap:397.01M
PE:-3.65
High:9.07
Open:9.07
Low:8.60
Close:9.17
52wk High:25.96
52wk Low:4.68
Shares:45.90M
Float Shares:37.58M
Volume Ratio:1.15
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3710
EPS(LYR):-2.2432
ROE:-28.21%
ROA:-18.47%
PB:1.06
PE(LYR):-3.86

Loading ...

BioAge Labs is Maintained at Buy by Needham

Dow Jones
·
Aug 01

Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)

TIPRANKS
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

BioAge Labs price target lowered to $25 from $36 at Roth Capital

TIPRANKS
·
Aug 01

Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential

TIPRANKS
·
Aug 01

BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

TIPRANKS
·
Aug 01

BioAge Labs price target lowered at Jefferies after Novo trial miss

TIPRANKS
·
Aug 01

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

TIPRANKS
·
Aug 01

BioAge Labs Down over 61%, on Pace for Largest Percent Decrease Since December 2024

Dow Jones
·
Aug 01

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Sales of Leqembi® Totaled 29.3 Billion Yen in the Second Quarter 2026

THOMSON REUTERS
·
Jul 29

How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure

Simply Wall St.
·
Jul 10

Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20

Reuters
·
Jul 02

BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus

TIPRANKS
·
Jun 19

Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Jun 17

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Jun 17

BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102

Reuters
·
Jun 16

Bioage Labs - Topline Data From Quell-Cv Trial Anticipated in Second Half of 2026

THOMSON REUTERS
·
Jun 16

Bioage Labs Announces First Participant Dosed in Quell-Cv, a Phase 2 Proof-of-Concept Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Patients at Elevated Cardiovascular Risk

THOMSON REUTERS
·
Jun 16

Bioage Labs - to Initiate Phase 1B/2a Trial of Bge-102 in Dme in Mid-2026

THOMSON REUTERS
·
Jun 16